Company:  VICAL INC (VICL)
Form Type:  8-K
Filing Date:  8/1/2013 
CIK:  0000819050 
Address:  10390 PACIFIC CENTER COURT
.
 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$1.49  
Change: 
0.02 (1.36%)  
Trade Time: 
12:57 PM EST  
Market Cap: 
$32.50M
Trade VICL now with 

© 2018  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have three active development programs in the area of infectious disease comprised of: * An ongoing Phase 2 trial of our HSV-2 therapeutic vaccine, VCL-HB01, to treat patients with symptomatic genital herpes infection. The vaccine candidate is currently being evaluated in a Phase 2 study in adult subjects, 18 to 50 years of age who are randomized 2:1 to receive either vaccine or placebo. Recruitment of 261 subjects at 15 U.S. clinical sites was completed in April 2017 and dosing was completed in July 2017.
Register and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
    INDEX TO EXHIBITS
  EXHIBIT 99
    INCOME STATEMENT